Neurostimulation to treat memory loss, improving clinical outcomes for women’s health, identifying novel drug targets for chronic pain, wireless drug delivery, and opioid risk prediction. These are among the areas of interest for companies taking part in the life science track of the startup pitch contest at INVEST Precision Medicine.
The life science track of the Pitch Perfect contest is set for Thursday, June 10 at 3:30 pm-5 pm ET.
The contest is part of a three day online conference exploring different aspects of precision medicine and life science innovation. To view the full agenda, click here. There is no charge to register.
The companies presenting include:
Prenome is a women’s health company focused on improving clinical outcomes with leading edge technologies in data-driven personalized medicine. Prenome’s platform enables the early identification of risks and individualized interventions to lower costs and improve outcomes across the women’s health care continuum without reliance on expensive treatments and therapeutics. Its platform has been developed in collaboration with the leading experts in women’s health and personalized medicine. The company currently partners with healthcare providers and payers to improve patient care by integrating the Prenome platform into routine workflow.
Presenter: Steve Cline, co-founder and CEO
Headquarters: San Francisco, California
Nia Therapeutics is developing implantable brain stimulation device for the treatment of memory loss. Memory loss affects over 20 million Americans with traumatic brain injury and degenerative disease, resulting in significant decreases in productivity and quality of life. Nia’s proprietary medical device platform utilizes brain sensing and artificial intelligence to develop a personalized therapy for each patient based upon their unique pattern of brain activity. Its technology was developed at the University of Pennsylvania with $24 million in funding from DARPA. Its team has demonstrated proof of concept of its ability to improve human memory in neurosurgical patients. Nia’s first clinical target is memory loss due to traumatic brain injury, a $32 billion whitespace market.
Presenter: Dan Rizutto, PhD, CEO
Headquarters: Philadelphia, Pennsylvania
Doloromics is a spin-out from the University of Texas at Dallas. Founded in 2020, the goal of Doloromics is to identify novel drug targets for chronic pain using our proprietary DOLOReS algorithm.
Presenter: Candler Paige, CEO
Headquarters: Dallas, Texas
SmartTab is engaged in the design, development and validation of next generation wireless drug delivery systems. The SmartTab technology platform is a personalized wireless solution comprised of an ingestible capsule with a microprocessor, smart polymer actuator, and active ingredients. SmartTab is on a mission to provide novel effective therapies to improve patient outcomes and compliance.
Presenter: Robert Niichel, Founder and CEO
Headquarters: Denver, Colorado
OpalGenix’s patented genotype-based opioid risk prediction and clinical decision support platform, GPS-Opioid, empowers clinicians to personalize therapy for patients who require opioids for pain. In the U.S., 30 million adult and pediatric patients are given opioids for pain relief after surgical procedures annually. Each person responds differently to opioids based on genetics and clinical factors, making medication management challenging for physicians. GPS-Opioid assesses each patient’s risk of opioid adverse effects and personalizes opioid selection and dosing to maximize pain relief and minimize opioid-related safety risks and costs. OpalGenix has completed pediatric clinical studies, obtained USPTO and European patent claims, and received notice of intent to fund an NIH STTR grant proposal.
Presenter: Senthilkumar Sadhasivam
Headquarters: Indianapolis, Indiana
There are three judges for the life science track. They include:
Photo: AdrianHillman, Getty Images
